Skip to main content
. 2011 Aug 11;4(3):299–311. doi: 10.1007/s12307-011-0079-2

Fig. 1.

Fig. 1

Bone targeted therapies. Recent progress in the pathogenesis of bone disease and myeloma biology have accelerated our understanding of the effects of current treatment on myeloma and associated bone disease, more importantly they have translated into the development of novel bone-targeted agents